Spago Nanomedical AB (publ) (SPAGO.ST)
SEK 0.19
(7.39%)
SEK 0.19
(7.39%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -45.21 Million SEK | 27.19% |
| 2022 | -62.1 Million SEK | -18.38% |
| 2021 | -52.46 Million SEK | -84.41% |
| 2020 | -28.44 Million SEK | -134.16% |
| 2019 | -12.14 Million SEK | 26.24% |
| 2018 | -16.47 Million SEK | 45.67% |
| 2017 | -30.31 Million SEK | -182.46% |
| 2016 | -10.73 Million SEK | 31.75% |
| 2015 | -15.72 Million SEK | -2923.16% |
| 2014 | 557 Thousand SEK | -92.96% |
| 2013 | 7.91 Million SEK | 136.0% |
| 2012 | -21.97 Million SEK | -1534.05% |
| 2011 | -1.34 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -47.7 Million SEK | -47.91% |
| 2024 Q1 | -32.25 Million SEK | 28.68% |
| 2023 Q3 | -25.97 Million SEK | 17.26% |
| 2023 FY | -45.21 Million SEK | 27.19% |
| 2023 Q4 | -45.21 Million SEK | -74.09% |
| 2023 Q2 | -31.39 Million SEK | 30.4% |
| 2023 Q1 | -45.1 Million SEK | 27.37% |
| 2022 FY | -62.1 Million SEK | -18.38% |
| 2022 Q3 | -71.23 Million SEK | -142.18% |
| 2022 Q2 | -29.41 Million SEK | 28.24% |
| 2022 Q1 | -40.99 Million SEK | 21.86% |
| 2022 Q4 | -62.1 Million SEK | 12.82% |
| 2021 FY | -52.46 Million SEK | -84.41% |
| 2021 Q2 | -76.87 Million SEK | 9.8% |
| 2021 Q3 | -65.98 Million SEK | 14.16% |
| 2021 Q4 | -52.46 Million SEK | 20.5% |
| 2021 Q1 | -85.22 Million SEK | -199.58% |
| 2020 Q3 | -35.69 Million SEK | 13.81% |
| 2020 Q1 | -6.93 Million SEK | 42.89% |
| 2020 Q4 | -28.44 Million SEK | 20.31% |
| 2020 FY | -28.44 Million SEK | -134.16% |
| 2020 Q2 | -41.42 Million SEK | -497.02% |
| 2019 FY | -12.14 Million SEK | 26.24% |
| 2019 Q1 | -7.85 Million SEK | 52.29% |
| 2019 Q2 | -33.15 Million SEK | -321.9% |
| 2019 Q3 | -22.98 Million SEK | 30.68% |
| 2019 Q4 | -12.14 Million SEK | 47.14% |
| 2018 Q3 | -28.19 Million SEK | -32.2% |
| 2018 FY | -16.47 Million SEK | 45.67% |
| 2018 Q4 | -16.47 Million SEK | 41.58% |
| 2018 Q2 | -21.32 Million SEK | 25.26% |
| 2018 Q1 | -28.53 Million SEK | 5.87% |
| 2017 Q1 | -6.3 Million SEK | 41.24% |
| 2017 FY | -30.31 Million SEK | -182.46% |
| 2017 Q3 | 4.02 Million SEK | 413.32% |
| 2017 Q4 | -30.31 Million SEK | -853.52% |
| 2017 Q2 | -1.28 Million SEK | 79.64% |
| 2016 Q1 | -10.63 Million SEK | 32.36% |
| 2016 FY | -10.73 Million SEK | 31.75% |
| 2016 Q4 | -10.73 Million SEK | 31.46% |
| 2016 Q3 | -15.65 Million SEK | 22.79% |
| 2016 Q2 | -20.27 Million SEK | -90.66% |
| 2015 Q2 | 8.08 Million SEK | 113.04% |
| 2015 Q1 | 3.79 Million SEK | 581.69% |
| 2015 FY | -15.72 Million SEK | -2923.16% |
| 2015 Q4 | -15.72 Million SEK | -238.84% |
| 2015 Q3 | 11.32 Million SEK | 40.02% |
| 2014 Q1 | 11.22 Million SEK | 41.81% |
| 2014 Q4 | 557 Thousand SEK | 119.59% |
| 2014 FY | 557 Thousand SEK | -92.96% |
| 2014 Q2 | -6.37 Million SEK | -156.77% |
| 2014 Q3 | -2.84 Million SEK | 55.35% |
| 2013 Q2 | -7.29 Million SEK | 22.71% |
| 2013 FY | 7.91 Million SEK | 136.0% |
| 2013 Q1 | -9.43 Million SEK | 57.08% |
| 2013 Q3 | -4.58 Million SEK | 37.09% |
| 2013 Q4 | 7.91 Million SEK | 272.49% |
| 2012 FY | -21.97 Million SEK | -1534.05% |
| 2012 Q3 | -415.65 Thousand SEK | 0.0% |
| 2012 Q4 | -21.97 Million SEK | -5187.52% |
| 2011 FY | -1.34 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -50.02 Million SEK | 9.604% |
| Ziccum AB (publ) | -2.13 Million SEK | -2015.91% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | -137.235% |
| BioArctic AB (publ) | -606.58 Million SEK | 92.546% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | 9.446% |
| Mendus AB (publ) | -96.29 Million SEK | 53.043% |
| Genovis AB (publ.) | -43.94 Million SEK | -2.904% |
| Intervacc AB (publ) | -88.16 Million SEK | 48.71% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 320.463% |
| Active Biotech AB (publ) | -33.2 Million SEK | -36.196% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 184.958% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | -14.816% |
| Aptahem AB (publ) | 2.9 Million SEK | 1654.574% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 86.447% |
| Kancera AB (publ) | -45.69 Million SEK | 1.04% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 86.259% |
| Fluicell AB (publ) | -2.76 Million SEK | -1536.518% |
| Saniona AB (publ) | 40.44 Million SEK | 211.793% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | -41.626% |
| Biovica International AB (publ) | -58.73 Million SEK | 23.018% |
| AcouSort AB (publ) | -23.98 Million SEK | -88.514% |
| Xintela AB (publ) | -7.8 Million SEK | -479.037% |
| Abliva AB (publ) | -57.24 Million SEK | 21.005% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 76.776% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 44.993% |
| OncoZenge AB (publ) | -12.62 Million SEK | -258.098% |
| Amniotics AB (publ) | -5.63 Million SEK | -702.859% |
| 2cureX AB (publ) | -13.4 Million SEK | -237.365% |
| CombiGene AB (publ) | -101.44 Million SEK | 55.425% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -1992.411% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 937.352% |
| Camurus AB (publ) | -1.16 Billion SEK | 96.12% |
| Corline Biomedical AB | -17.01 Million SEK | -165.795% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 46.005% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 67.269% |
| I-Tech AB | -83.26 Million SEK | 45.693% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 133.567% |
| Cyxone AB (publ) | -16.67 Million SEK | -171.248% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | 19.091% |
| Biosergen AB | -1.88 Million SEK | -2301.328% |
| Cantargia AB (publ) | -139.74 Million SEK | 67.644% |
| NextCell Pharma AB | -46.79 Million SEK | 3.363% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 65.082% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | -53.888% |
| Nanologica AB (publ) | -9.38 Million SEK | -381.647% |
| SynAct Pharma AB | -61.75 Million SEK | 26.784% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | -111.146% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | -241.797% |
| LIDDS AB (publ) | -13.51 Million SEK | -234.643% |
| Lipum AB (publ) | -8.46 Million SEK | -434.164% |
| BioInvent International AB (publ) | -236.3 Million SEK | 80.865% |
| Alzinova AB (publ) | -21.22 Million SEK | -113.026% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 32.431% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -772.76% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 46.004% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -4798.917% |
| Simris Alg AB (publ) | 85.07 Million SEK | 153.15% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 44.915% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 127.227% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | -117.463% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -1421.433% |